Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
Focus Adverse reactions
Acronyms HIT

09 Jul 2019 Status changed from active, no longer recruiting to completed.
07 Apr 2018 Results (n=19) of phase1 part of study assessing tolerability and efficacy of intrathecal trastuzumab administration for the treatment of patients with metastatic HER2-positive breast cancer, developing carcinomatous meningitis, were published in the European Journal of Cancer.
02 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com